Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice—EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study2015 · 40 citations
2. 2Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials2016 · 374 citations
3. 3A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management2015 · 2,711 citations
4. 4The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial2015 · 85 citations
5. 5GLP-1 and weight loss: unraveling the diverse neural circuitry2016 · 292 citations